The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
BACKGROUND
The BRAF(V600E) mutation, which accounts for about 60-80% papillary thyroid carcinoma(PTC), has been identifiedas a prognostic marker for risk stratification of PTC patients. However, the BRAF(V600E) mutation as a prognostic marker in papillary thyroid microcarcinoma (PTMC) is unclear.


METHODS
We performed a retrospective review of 101 patients who underwent surgery for PTMC. We studied the prevalence of the BRAF(V600E) mutation. The associations between the BRAF(V600E) mutation and clinicopathologic characteristics were analyzed.


RESULTS
The BRAF(V600E) mutation was observed in 72 patients (71.3%). There was no statistically significant correlation in age, gender, multifocality, extrathyroidal extension, presence of Hashimoto thyroiditis, and lymph node metastasis between the BRAF(V600E) mutant group and wild group.


CONCLUSIONS
The BRAF(V600E) mutation is not significantly associated with prognostic factors in PTMC.
Sun Yi
SY
Choi
Heonsoo
H
Park
Myung Koo
MK
Kang
Dong Kun
DK
Lee
Kang Dae
KD
Lee
Hyoung Shin
HS
Lee
Sung Won
SW
Kim
Eun Nam
EN
Lee
Department of Otolaryngology-Head and Neck Surgery, Dong-A University of College of Medicine, 3-1 Dongdaeshin-Dong, Busan, Seo-Gu 602-715, South Korea. santa@dau.ac.kr.
Jong Chul
JC
Hong
D002291:Carcinoma, Papillary / Q000235:genetics* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000473:pathology
C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf